Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G.
Loupakis F, et al. Among authors: bocci g.
Br J Cancer. 2011 Apr 12;104(8):1262-9. doi: 10.1038/bjc.2011.85. Epub 2011 Mar 15.
Br J Cancer. 2011.
PMID: 21407216
Free PMC article.
Clinical Trial.